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Abstract
It is 30 yr since the British Journal of Anaesthesia published the ﬁrst consensus protocol for the laboratory diagnosis of malignant
hyperthermia susceptibility from the EuropeanMalignant Hyperthermia Group. This has subsequently been used inmore than
10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant
hyperthermia during general anaesthesia, representing an early and successful example of stratiﬁed medicine. In 2001, our
group also published a guideline for the use of DNA-based screening ofmalignant hyperthermia susceptibility.We now present
anupdated and complete guideline for the diagnostic pathway for patients potentially at increased riskof developingmalignant
hyperthermia. We introduce the new guideline with a narrative commentary that describes its development, the changes to
previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and
clinical interpretation of laboratory ﬁndings.
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The European Malignant Hyperthermia Group (EMHG) was
formed in 19831 with the principal objective of standardizing
the laboratory diagnosis of malignant hyperthermia (MH) sus-
ceptibility. At that time, pharmacological challenge tests carried
out on excised skeletal muscle biopsies were being used for this
purpose by several groups in North America, Europe, South Africa,
and Australia. These tests were based on the ﬁndings that MH
muscle samples weremore sensitive to the contracture-inducing
properties of caffeine, or caffeine with halothane,2 or halothane
alone3 than normal muscle, but with such interlaboratory vari-
ation that comparisons of resultswere impossible. One particular
area of contention was the combined caffeine–halothane test,
which had proponents in North America but not in Europe. In
1984, the EMHG published its protocol for an in vitro contracture
test (IVCT),4 and this has formed the bedrock of clinical diagnosis
and phenotyping for research in Europe throughout the past
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30 yr. The protocol has been the subject of annual review by the
EMHG and, since the launch of the EMHG website (www.emhg.
org), the latest version of the protocol has been available on-
line. Member laboratories of the EMHG participate in a quality as-
surance-programme, with a principal focus on compliance with
the protocol.
Although the protocol was developed through an informal
consensus approach, it was based on the collective experience
of the EMHG founding members, which in 1984 already encom-
passed investigation by muscle biopsy of more than 1500 indivi-
duals at risk of MH susceptibility either through a history of a
suspected MH reaction or a family history. In 1984, there was no
obvious means of validating the test because there were insufﬁ-
cient data on the outcome of the test in low-risk individuals and
no consensus on the clinical criteria for assigning ‘true-positive’
status without recourse to results of the IVCT. After the publica-
tion of a clinical grading scale5 and accumulation of results of the
IVCT in low-risk individuals, an evaluation of the EMHG became
feasible.6 This conﬁrmed that the IVCTwas not speciﬁc (point es-
timate for speciﬁcity of 94%) because some low-risk individuals
had positive IVCT responses. It is possible that some of these
false-positive results arose from the use of atrophied muscle, be-
cause muscle sampled during the course of ipsilateral joint ar-
throplasty was included. The reported point estimate for the
sensitivity of the IVCTwas 99%. However, examination of the sin-
gle patient (patient 4)6 who reduced the sensitivity from 100% re-
veals that the authors misapplied the Clinical Grading Scale,5
which speciﬁcally excludes rigidity on emergence of general an-
aesthesia as an indicator of MH. The Clinical Grading Scale score
for this patient should have been amaximum of 35, therefore ex-
cluding this patient from the category of ‘almost certain’MHused
to determine the sensitivity of the test. It seems likely that this
was an instance of iatrogenic hyperthermia and possible febrile
convulsion in an infantwho had received atropine before surgery
and overly enthusiastic warming during surgery.
The rigour of the IVCT is also evident from its use to pheno-
type members of MH families in molecular genetic studies. The
IVCT, and its North American equivalent, enabled the linkage
analyses that identiﬁed RYR1 as the major locus implicated in
MH.7 8 During the 1990s, results from the IVCT suggested, to the
scepticism of many geneticists at the time, that RYR1 was not
involved in all MH patients9–11 and that more than one genetic
factor was likely to be implicated in some families.12 13 The ro-
bustness of the IVCT has been borne out by its use to identify a
second locus (CACNA1S)11 14 and provide further evidence for
the involvement of interacting gene products.15 16 The complex-
ity of the genetics of MH, which would not have been realized
without the IVCT, has been conﬁrmed further by early results
of next-generation sequencing in MH families.17 18 Although
the EMHG appreciated the complexity of the genetics of MH,
through collaborative working of its multidisciplinary member-
ship it developed guidelines for the use of molecular genetic
techniques in order to reduce the need for a muscle biopsy in
selected patients, while recognizing that MH susceptibility
could be excluded for clinical purposes only with the use of the
IVCT. These guidelineswere published in 200119 and subsequently
evaluated.20
In 2012, the executive committee of the EMHG instigated a
major review of the IVCT protocol and, in the course of this re-
view, decided that a complete guideline for the diagnosis of MH
susceptibility would be useful, including updated advice on the
use genetic screening. The guideline has been drafted by a writ-
ing committee, with two rounds of consultationwith representa-
tives from each member laboratory of the EMHG. The ﬁnal
version of the guideline (Appendix 1) was agreed by the EMHG
in May 2014. We will now discuss the rationale for elements of
the guideline that were not included in either the IVCT protocol
or the previous genetic diagnosis guideline, and the major
changes to these previous documents.
Patient referral criteria
This is a new addition to previous guidelines. For possible malig-
nant hyperthermia reactions during general anaesthesia, we
considered using the score provided by the Clinical Grading
Scale.5 This can provide an estimate of the likelihood of a malig-
nant hyperthermia reaction, but the decision required in the
diagnostic setting is whether MH can be excluded or not, for
which the Clinical Grading Scale is generally not helpful. When
MH cannot be excluded (for example, by identiﬁcation of a
more likely explanation for the signs, inconsistency of the signs
with MH, or both), referral is indicated.
The referral criteria also reﬂect our current understanding of
events that, in themselves, are notmalignant hyperthermia reac-
tions (a progressive life-threatening hyperthermic reaction dur-
ing general anaesthesia), but are possible manifestations of the
underlying genetic defect(s) leading to malignant hyperthermia
susceptibility. Many such manifestations have been proposed
over the years, such as sudden infant death syndrome,21 but
most have not stood up to robust analysis.22 There is now strong
evidence that some patients susceptible to MH are at increased
risk of developing rhabdomyolysis secondary to heavy exercise23
but also to several other known causes of rhabdomyolysis.24
There are, of course, other causes of recurrent rhabdomyolysis,
and investigation for these by a neurologist should be done in
conjunction with an MH referral centre. This will enable sequen-
cing of RYR1 and CACNA1S at the same time as genetic screening
of other genes associated with rhabdomyolysis, such as CPT2,
PYGM, ACADM, AMPD1, and VLCAD. If a muscle biopsy is indi-
cated in the course of neurological assessment, this should be
done in anMH centre so that samples for IVCT and for histologic-
al examination can be obtained and processed appropriately.
Persistently raised serum creatine kinase concentration was
ﬁrst documented in association with MH susceptibility before
the principle of the IVCT was established25 and was proposed
as a diagnostic test. The utility of creatine kinase concentration
is, however, limited because of a lack of sensitivity and speciﬁ-
city.26 In patients with so-called idiopathic hyperCKaemia,
where full neurological evaluation has excluded other causes,
investigation of MH susceptibility may be warranted.27 As with
patients with rhabdomyolysis, the neurologist should liaise
with an MH testing centre, where any muscle biopsy should be
carried out.
There is considerable overlap between the clinical features of
exertional heat illness andMH. Indeed, if diagnostic classiﬁcation
of heat illness, speciﬁcally the diagnosis of heat stroke, did not re-
quire a clinical assessment of mental function and level of con-
sciousness, a separate International Classiﬁcation of Disease
code for MH might not have emerged. Clearly, the deﬁnition of
MH as a condition occurring during general anaesthesia makes
any such assessment impossible. While there appears to be suf-
ﬁcient evidence to support a relationship between genetic predis-
position to exertional heat illness and MH susceptibility,28–30 the
evidence to deﬁne that relationship is less tangible.31 Amajor dif-
ferencewith implications for diagnostic strategy is thatMHarises
exclusively in individuals with a genetic predisposition, whereas
that seems likely in perhaps a minority of patients with exer-
tional heat illness. There are indeed well-recognized non-genetic
532 | Hopkins et al.
factors that predispose to exertional heat illness,32 and we rec-
ommend that these are excluded before further investigation, be-
cause the purpose of further tests is to identify individuals (and
their relatives) at risk of recurrent episodes, rather than to con-
ﬁrm the clinical diagnosis of heat illness per se.
The in vitro contracture test
Only very minor adjustments have been made to the technical
conduct of the IVCT compared with the last published version6
because the validation study revealed a clinically useful and ro-
bust test.6 One of these amendments is to stipulate an increased
minimal length of muscle specimen for use in the tests, because
muscle length has emerged as the major determinant of speci-
men viability (EMHG, unpublished data). The EMHG quality-as-
surance programme aims to guarantee control of the test bath
constituents and conditions, including concentration measure-
ments by a reference laboratory.
We have added a recommendation concerning the minimum
age and weight of children undergoing the procedure. Before for-
mation of the EMHG, therewere anecdotal reports of normal con-
tracture responses in young children (less than 3 yr of age)
considered, on clinical grounds, to have had an MH reaction.
The study that evaluated the sensitivity and speciﬁcity of the
IVCT included children as young as 4 yr of age6 and found no evi-
dence of reduced sensitivity of the IVCT in children of 4 yr of age
or older. However, most of the participating centres did not con-
tribute data from children younger than 10 yr of age and are not
minded to change their policy without more data on high-risk
and low-risk children. There are also concerns among some
members of the EMHG that there may be unacceptable cosmetic
and functional consequences of the muscle biopsy in children
below a certain body weight (e.g. 30 kg) because of the need to
obtain samples of the required length.
Themajor change in the protocol is in the laboratory diagnos-
tic classiﬁcation. In all previous versions of the protocol, patients
were classiﬁed, on the basis of the results of their IVCT responses,
into one of the following three groups: MHS (MH susceptible);
MHN (MH normal); or MHE (MH equivocal). Although the original
criteria for categorizing results were modiﬁed in 1985,33 the prin-
ciple was the same, such that patients with abnormal responses
to both halothane and caffeine were classiﬁed as MHS, patients
with normal responses to both halothane and caffeinewere clas-
siﬁed as MHN, and patients with an abnormal response to either
caffeine or halothane but not both were classiﬁed as MHE. While
this system undoubtedly proved beneﬁcial for some types of
collaborative research projects among EMHG members and for
comparing results from different diagnostic centres, it has its
limitations.
The ﬁrst limitation arose from the use of the term ‘equivocal’.
While this indeed reﬂected the uncertainty of the founder EMHG
members as to the clinical signiﬁcance of the MHE laboratory
classiﬁcation, there has been a consensus since 198533 that pa-
tientswith anMHE laboratory classiﬁcation should be considered
clinically at risk of developing MH under anaesthesia. The appro-
priateness of this approach has been borne out by a study that
evaluated the sensitivity and speciﬁcity of the protocol6 and the
results of genetic analyses. However, use of the ‘equivocal’ label
outside of its laboratory context has the potential to confuse pa-
tients and clinicians unfamiliar with its derivation. The changes
in the protocol are to address this problem such that the primary
designation of any patient with an abnormal response to either
or both caffeine and halothane tests is MHS. A sufﬁx is then
added to indicate an abnormal response to halothane (h) or
caffeine (c), so that there are now four laboratory diagnostic
groups: MHShc (formerly MHS); MHSh (formerly MHE); MHSc (for-
merly MHE); and MHN (unchanged).
The second limitation of the old (and indeed new) laboratory
classiﬁcation system is that it is crude, not using awealth of data
that can be derived from the contracture studies. This was best
appreciated at the outset of molecular genetic investigations of
MH susceptibility, because accurate phenotyping is essential
for robust genetics. The EMHG adopted, although never pub-
lished, a recommendation that the minimal data set for the
IVCT phenotype should be the threshold concentration (concen-
tration producing a contracture of 2 mN or 0.2 g force) of halo-
thane and caffeine, along with the tension produced at 2%
halothane and at 2 mM caffeine. Even more sophisticated ap-
proaches have been proposed,34 35 and the genetic basis for the
observed phenotypic variability has been published.36 We did,
therefore, consider introducing more sophistication into the re-
porting of IVCT results but pragmatically decided that the pri-
mary purpose of the test was to provide a categorical diagnosis
for clinical purposes with known sensitivity and speciﬁcity.
Clinical interpretation of in vitro contracture
test results
This is another addition to previous publications. It is a reminder
to the MH specialist that they must interpret laboratory ﬁndings
in the light of the totality of clinical and investigative data avail-
ability for the beneﬁt of non-specialists. It is the latter group of
clinicians who provide the great majority of medical care to MH
patients. The most fundamental role of MH diagnostics is to be
conservative in applying the diagnosis of not susceptible to MH
because false-negative diagnosis ismost likely to have disastrous
consequences. The evidence is that a laboratory diagnosis of
MHN by IVCT provides a high degree of security if carried out in
an EMHG-accredited laboratory that conducts the tests according
to this protocol and where the specimens fulﬁl the viability cri-
teria.6While the offspring of a patient tested MHN cannot inherit
MH susceptibility from that parent, it is still possible that they
may be susceptible by transmission from the other untested par-
ent or through a de novo genetic mutation; the probability of ei-
ther of these events is less than the population prevalence of
MH susceptibility.
Molecular genetic detection of susceptibility
to malignant hyperthermia
The original genetic guideline published in 2001 described the
potential diagnostic use of screening for 15 mutations in the
RYR1 gene shown to produce functional changes compatible
with a pathogenic role in appropriate model cell sytems.19 The
guideline also described the possibility of using genetic markers
that showed highly statistically signiﬁcant segregation with the
MH trait in individual families. A keymessage of those guidelines
was the need to conﬁrm MHN status using the IVCT in indivi-
duals who did not carry the familial RYR1 mutation or genetic
marker. This was because of reports of discordance between
RYR1 genotype and the IVCT phenotype in a number of families
across Europe. Evidence for a biological basis for these observa-
tions, rather than them being a consequence of test failings,
has accumulated since then.15 16 20 36 37
Recent evidence has also conﬁrmed the foresight of the previ-
ous guidelines in requiring functional analysis of missense
variants before their adoption for diagnostic use. Kim and
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colleagues18 reported the prevalence of rare RYR1 variants in a
control sample to be 6%. It is interesting that generic guidelines
for interpretation of ﬁndings of variants in other genes adopt a
similar approach.38 These generic guidelines also propose using
segregation analyses39 to indicate likely pathogenicity, but in
our experience it is rare to generate sufﬁcient statistical power
to enable this, even when combining data from several families
carrying the same variant.
Unfortunately, the costs and technical difﬁculties associated
with conducting rigorous functional analyses are rate limiting. Al-
though more than 180 RYR1 variants have been associated with
MH susceptibility, only 33 have been shown to have functional ef-
fects consistent with MH pathogenicity (www.emhg.org). Two
variants in CACNA1S have also been shown to be functionally
consistent with pathogenicity.40 41 The inclusion of the use of ex
vivo preparations for functional analysis is controversial (Appen-
dix 2), even with the safeguard that consistent results need to be
obtained using preparations derived from at least two unrelated
individuals. We consider that the balance of risk from misdiag-
nosis (false-positive diagnosis of MH susceptibility) is not sufﬁ-
cient to outweigh the beneﬁt of avoiding muscle biopsy in these
families, so long as the muscle biopsy and IVCT are required to
conﬁrm that an individual is not susceptible. If functional charac-
terization is done using the more rigorous genetic manipulation
of heterologous42 or homologous43 expression systems, we have
removed the need for the variant to have been described in
more than one family (Appendix 2), in line with generic guide-
lines.38 This recognizes thatmany variants are so far private to in-
dividualMH families.We also recognize that reports of functional
analyses of further RYR1 variantsmay not necessarily continue to
be easy to publish, and we have therefore removed the need for
functional analyses using previously described methods to be
published before accepting the relevant variant for diagnostic
use. Instead, reports of functional analyses will be peer reviewed
by members of the EMHG with the relevant expertise.
Advances in genetic technology have prompted a change in
our recommendations for the diagnostic pathway of patients re-
ferred for investigation of MH susceptibility (Fig. 1). Our previous
genetic testing guideline19 recommended muscle biopsy and
IVCT as the primary investigation for the index case, with subse-
quent mutation screening when the IVCT conﬁrmed MH suscep-
tibility.We now consider DNA screening to be a viable alternative
primary diagnostic approach to the IVCT.45 Themore than doub-
ling in number of functionally characterized variants associated
with MH susceptibility has increased the proportion of MH fam-
ilies able to beneﬁt from DNA diagnostics from ∼25% in 2001 to
more than 40% now (data extrapolated from Carpenter and col-
leagues).36 The potential expense in screening for these addition-
al variants has been more than compensated by the advances in
genetic technology.
Conclusion
The EMHG has led the way in the standardization and quality
assurance of diagnostic testing for MH susceptibility throughout
the past 30 yr. This new guideline updates and adds to previous
publications as an important contribution to the safety of
patients requiring general anaesthesia.
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Appendix 1: EuropeanMalignant Hyperthermia
Group guideline for the investigation of
malignant hyperthermia susceptibility
Investigation of malignant hyperthermia (MH) susceptibility ini-
tially involves clinical evaluation of a patient’s risk based on their
anaesthetic and medical history, and relevant family history.
Further investigation is indicated when increased risk of suscep-
tibility to MH cannot be excluded. The highest sensitivity for de-
tecting susceptibility to MH is provided by pharmacological
challenge tests carried out on freshly excised skeletal muscle in
controlled laboratory conditions. These tests, when carried out
according to the following protocol, are collectively referred to
as the in vitro contracture test, or IVCT. The IVCT is recommended
for individuals considered to be at increased risk ofMH either as a
ﬁrst-line test or when DNA analyses have failed to conﬁrm the
high-risk status. DNA analyses are less invasive than the IVCT
but not as sensitive. They have a major role in family screening
and, with recent improvements in cost-effectiveness of genotyp-
ing, can play a role in the primary investigation of index cases.45
A. Patient referral criteria
The following are the most common reasons for referral for
investigation of MH susceptibility.
1. Family history of MH.
2. Adverse reaction to general anaesthesia where a trigger
agent has been used, involving any combination of signs of
increased metabolism (unexplained increase in carbon
dioxide production, tachycardia, temperature increase), mus-
cle rigidity, rhabdomyolysis, disseminated intravascular co-
agulation or death, or both. Initial signs should be evident
during anaesthesia or within 60 min of discontinuation of
anaesthesia.
3. Family history of unexplained perioperative death.
4. Postoperative rhabdomyolysis after clinical exclusion of other
myopathies.
5. Exertional rhabdomyolysis, recurrent rhabdomyolysis, or per-
sistently raised serum creatine kinase concentration where
no cause has been identiﬁed after neurological work-up (idio-
pathic hyperCKaemia).
6. Exertional heat stroke requiring hospital admission, where
known predisposing factors have been excluded.
7. Myopathy and detection of an uncharacterized, rare, poten-
tially pathogenic RYR1 variant.
B. In vitro contracture test
1. The minimum patient age for the muscle biopsy is 4 yr, but
laboratories should not test children younger than 10 yr of
age without relevant control data. Laboratories may also set
minimum body weight limits.
2. The biopsy should be performed on the quadriceps muscle
(either vastus medialis or vastus lateralis), using local (avoiding
local anaesthetic inﬁltration of muscle tissue), regional, or
trigger-free general anaesthetic techniques.
3. The muscle samples can be dissected in vivo or removed as a
block for dissection in the laboratory within 15 min.
4. The excised muscle should be placed immediately in precar-
boxygenated Krebs–Ringer solution of the following compos-
ition (in millimoles per litre): NaCl, 118.1; KCl, 3.4; MgSO4, 0.8;
KH2PO4, 1.2; glucose, 11.1; NaHCO3, 25.0; and CaCl2, 2.5 (pH
7.4). Freshly made or pharmaceutically stable Krebs–Ringer
solution should be used. The ion concentration should be as
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stated with a maximum deviation of (10%), and its pH should
be in the range 7.35–7.45 at 37°C.
5. The muscle should be transported to the laboratory in Krebs–
Ringer solution at ambient temperature. In the laboratory, it
should be kept at room temperature and carboxygenated.
6. The time from biopsy to completion of the tests should not
exceed 5 h.
7. The tests should be performed at 37°C in a tissue bath
perfused either intermittently or continuously with Krebs–
Ringer solution and carboxygenated continuously. At least
four tests should be performed, each one using a fresh speci-
men. These include two static caffeine tests (see 11 below)
and two halothane tests. The halothane test could consist
of either one static (see 12 below) and one dynamic test (see
13 below) or two static tests. Each laboratory should be con-
sistent in the method used. Separate tissue baths should be
used for different agents.
8. Muscle specimen dimensions.Muscle specimens suitable for
in vitro investigation should measure 20–25 mm in length be-
tween ties, with a thickness of 2–3 mm. For measurement of
length, see 8 below. The weight of the specimens should be
100–200 mg. The specimens are blotted and weighed after
the test, between sutures.
9. Determination of specimen length and predrug force.The sta-
tic tests (see 11 and 12 below) are performed at optimal length
(l0) which is determined 5 min after suspension of the speci-
men in the tissue bath by slowly stretching the muscle to
force of 2 mN (0.2 g). The length between sutures is measured
(initial length). Leave the muscle for another 4 min at initial
length, then commence electrical stimulation (see 10 below)
and stretch the muscle slowly until optimal twitch results
are obtained (usually corresponding to 2–3 g or to 120–150%
of initial length). This new length is considered to be the
optimal length (l0) and is recorded. The muscle is left at
optimal length (l0) to stabilize for at least 15 min and until
baseline force does not vary more than 2.0 mN (0.2 g) within
a 10 min period. Drugs may then be added. The baseline
force immediately before addition of drug is recorded as
the predrug force.
10. Electrical stimulation. To demonstrate viability, the muscle
specimen should be electrically stimulated (ﬁeld stimulation)
with a 1–2 ms supramaximal stimulus at a frequency of 0.2
Hz. After suspension of the muscle in the tissue bath and
with themuscle at optimal length, current or voltage is slowly
increased until twitch height does not increase anymore (ini-
tial stimulus intensity). For the supramaximal stimulation,
the current or voltage is increased to 120% of initial stimulus
intensity.
11. The static cumulative caffeine test and measurement of the
caffeine threshold. The concentrations of caffeine (as free
base, analytical grade) in the tissue bath should be increased
stepwise as follows: 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, and 32 mmol
litre−1. Each successive concentration of caffeine should be
administered as soon as the maximal contracture plateau in-
duced by the previous concentration of caffeine has been
reached, or after exposure of the muscle to the caffeine con-
centration for 3 min if no contracture occurs. The muscle is
not washed with fresh Krebs–Ringer solution between suc-
cessive concentrations of caffeine. Caffeine should be added
to the tissue bath either as a bolus by injection or, with low-
volume (<5 ml) baths, in the Krebs–Ringer perfusate. A rapid
change of caffeine concentrationmust be achieved. The result
of this test will be reported as the threshold concentration,
which is the lowest concentration of caffeine that produces
a sustained increase of at least 2 mN (0.2 g) in baseline force
from the lowest force reached. In addition, the maximal con-
tracture achieved at a caffeine concentration of 2mmol litre−1
should be reported. Please note that the lowest force is not ne-
cessarily the same as the predrug force.
12. The static halothane test and measurement of static halo-
thane threshold. The halothane threshold is obtained using
the halothane concentrations 0.11, 0.22, 0.44, and an optional
concentration of 0.66mmol litre−1 as equivalent to 0.5, 1.0, 2.0,
and 3.0 Vol%, respectively, from a serviced and calibrated
vaporizer. It is recommended that the halothane concentra-
tion in the gas phase should be measured close to the inlet
port of the tissue bath or the tissue bath concentration should
be measured regularly using gas chromatography, or both
(see under Quality Control, below). The specimen should be
exposed to each halothane concentration for at least 3 min
or until maximal contracture is reached. The result of this
test will be reported as the threshold concentration, which
is the lowest concentration of halothane that produces a con-
tracture of at least 2 mN (0.2 g) measured as an increase in
baseline force from the lowest force reached. The measure-
ment of halothane should also be reported. For determination
of halothane concentration, see 14 below. The ﬂow rate of gas
should be set tomaintain the correct halothane concentration
in the tissue bath. The gas ﬂow into the tissue bath should
be controlled using a low-ﬂow rotameter or similar device,
situated close to the inlet port of the tissue bath. The time to
reach equilibration of the halothane concentration in the
bath should be determined in order to ensure that the muscle
sample is exposed to the test drug for the required period. The
equilibration time will depend on bath volume, gas ﬂow rate,
rate of perfusion, and the dynamics of the tissue bath.
13. The dynamic halothane test and measurement of dynamic
halothane threshold. This test requires a motor to enable
stretching and relaxation cycles of the muscle specimen at
predeﬁned constant rates. Initially, the muscle is stretched
at a constant rate of 4 mm min−1 to achieve a force of ∼30
mN (3 g) and held at this new length for 1 min. The stretching
process is then reversed for 1.5 min. The movement of
the transducer from the end of the 1 min rest period to the
low force is measured accurately using a vernier scale. This
measurement is then used to achieve all subsequent
length–tension curves; themuscle is stretched and shortened
6 mm in each cycle. The muscle is allowed to rest for 3 min.
The process is then repeated to obtain three control curves
with 1 min rest at high force and 3 min rest at low force. At
the end of the descent of the third control curve, the muscle
is exposed to halothane at 0.11 mmol litre−1 (0.5%) for 3
min, and the stretch process is repeated. The procedure is
repeated for halothane concentrations of 0.22 and 0.44
mmol litre−1 (1 and 2%, respectively). The force is measured
at the end of the 1 min rest after stretching, and the dynamic
halothane threshold is the lowest concentration increasing
force 2 mN (0.2 g). The contracture at 0.44 mmol litre−1 is
also recorded.
14. Laboratory diagnostic classiﬁcation
• MHShc: a caffeine threshold (as deﬁned earlier) at a caffeine
concentration of 2.0 mmol litre−1 or less in at least one
caffeine test, and a halothane threshold concentration at
0.44 mmol litre−1 or less in at least one halothane test.
• MHSh: a halothane threshold concentration at 0.44 mmol
litre−1 or less in at least one halothane test and a caffeine
threshold at a caffeine concentration of 3 mmol litre−1 or
more in all caffeine tests.
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• MHSc: a caffeine threshold at a caffeine concentration of 2.0
mmol litre−1 or less and a halothane threshold concentra-
tion above 0.44 mmol litre−1 in all halothane tests.
• MHN: a caffeine threshold at a caffeine concentration of
3 mmol litre−1 or more in all caffeine tests and a halothane
threshold concentration above 0.44 mmol litre−1 in all halo-
thane tests.
15. Quality control. Viability in any specimen used should be de-
monstrated by twitches ≥10mN (1 g) at the beginning of a test
and, for the caffeine test, a response to 32 mmol litre−1 ≥50
mN (5 g) at the end. The concentrations of halothane and caf-
feine in the tissue bath should be checked at least every 6
months. The samples should be obtained directly from the
tissue bath in the same dynamic conditions as when testing.
Samples for determination of halothane concentrations
should be obtained immediately after the gas ﬂow has been
stopped to avoid sampling from the gas phase. Halothane
concentrations can be measured using gas chromatography
or high performance liquid chromatography and caffeine
using ultraviolet spectroscopy. Halothane 0.11 and 0.44
mmol litre−1 and caffeine 0.5 and 2 mmol litre−1 should be
checked. Accepted maximal deviation from the desired con-
centrations are (10%). Lambda halothane (air/Krebs–Ringer
solution) is taken to be 0.72 at 37°C. The vaporizer should be
serviced and calibrated in accordance with the manufac-
turer’s recommendations.
16. Control biopsies. Prospective MH units should test 30 control
muscle samples according to this protocol before commen-
cing their diagnostic programme. AllMHunits are asked to in-
vestigate further control samples when feasible. For control
samples, the following groups of patients are considered suit-
able: healthy volunteers; patients having amputations for
localized disease (not systemic or vascular disease); patients
with varicose veins; brain-dead patients within the ﬁrst
24 h; and patients with fractures within the ﬁrst 24 h. Control
biopsies should be conductedwithin the ethical framework of
the local institutional review board or ethics committee.
17. Optional tests. Tests with other drugs may be performed on
an optional basis. Results of optional tests are not used for
diagnosis. However, to allow for comparison of results be-
tween centres it is recommended that optional tests are per-
formed in a uniform way, agreed upon by the European
Malignant Hyperthermia Group (EMHG) Board of Directors.
At present, protocols exist for tests with ryanodine, sevoﬂur-
ane, and 4-chloro-m-cresol. These protocols may be accessed
through the EMHG homepage (www.emhg.org).
18. Protocol review. The EMHG protocol for investigation of MH
susceptibility by IVCT is reviewed annually.
C. Clinical interpretation of in vitro contracture
test results
Clinical advice provided by the diagnostic laboratory director re-
mains the responsibility of the individual physician. All available
information should be taken into account, including clinical
evaluation and IVCT results. Muscle histopathology, serum
biochemistry, and molecular genetic analysis may provide
additional information. However, in general all patients with
any subtype of MHS IVCT classiﬁcation should be considered
at risk of developing malignant hyperthermia under anaes-
thesia. Laboratory MHN diagnosis is good evidence that the
patient is not at increased risk of developing malignant
hyperthermia. An MHN-tested individual cannot transmit
MH risk to their offspring.
D. Molecular genetic detection of susceptibility
to malignant hyperthermia
Although an MH episode must be considered a multifactorial se-
quence of events, the genetic basis forMH susceptibility is largely
attributable to mutations in the RYR1 gene. Despite several link-
age and screening studies, mutations associated with MHS have
been found only in RYR1 and, more rarely, in CACNA1S, the gene
for the skeletal muscle L-type voltage-dependent Ca2+ channel
(Cav1.1 or DHPR).
The great majority of mutations reported in RYR1 result in the
replacement of an individual amino acid. With the currently
available algorithms, it is challenging to predict the functional
consequence of a given amino acid substitution within a large
tetrameric protein complex, such as the skeletal muscle ryano-
dine receptor, RYR1. We include, as Appendix 2, an updated
guideline for the interpretation of RYR1 sequence variants in
order to classify them as MH associated or not. The same princi-
ples should be applied to variants in CACNA1S and other genes
implicated in the future. A list of provenMH-associated RYR1mu-
tations is available on the EMHG website (www.emhg.org).
1. Predictive testing based on a known familial mutation. If an
MH-associated RYR1 mutation has been identiﬁed in the
index case (i.e. a person who has a clinical history consistent
with MH or who has a clearly positive IVCT result), the RYR1
mutation can be used for predictive genetic testing of rela-
tives. Persons at risk who are found to carry the familial mu-
tation should be regarded as MH susceptible (i.e. at increased
risk of developingMH in triggering anaesthetic conditions). In
contrast, persons at risk who do not carry the familial muta-
tion cannot be regarded as completely risk free. This is be-
cause of the limited sensitivity of the tests. It is known from
the study of large pedigrees that in ∼5% of patients the IVCT
results and genetic data are discordant. Should such persons
seek maximal safety, an IVCT should be considered.
2. RYR1 mutation screening as a diagnostic test. A number
of genetic testing methods are available for mutation screen-
ing of RYR1 either as targeted analysis of the known MH-
associated mutations or as screening of the entire coding
regions. Irrespective of the methods applied, a clear clinical
indication is a prerequisite for genetic testing [i.e. either a
positive IVCT (any subtype of MHS) or a clinically suspected
MH episode]. If one of the known MH-associated mutations
has been identiﬁed, the person should be considered at in-
creased risk of developing MH in triggering anaesthetic con-
ditions. In the absence of an RYR1 mutation, a disposition to
MH cannot be excluded. The decision on the next diagnostic
steps must then be based on the clinical indication. When
the entire coding region of RYR1 is being screened, as yet
unclassiﬁed sequence variants will frequently be identiﬁed.
The genetic laboratory is responsible for checking the avail-
able published evidence (literature and databases) and for
applying prediction algorithms with the aim of eventually
classifying the variant as neutral or potentially MH asso-
ciated. For patient safety, individuals carrying a ‘potentially
MH-associated’ RYR1 variant should be regarded as at in-
creased risk for MH until further diagnostic tests (i.e. an
IVCT) have been performed.
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Appendix 2: Characterization of RYR1
sequence variants
1. Genetic characterization. Each variant should be fully charac-
terized at the genetic level, including:
• A full description at the DNA and protein level, considering
aspects of evolutionary conservation and change in charge,
polarity, or structure introduced by the amino acid
replacement;
• Co-segregation of the variant with the disease in the family
or families affected; and
• Assessment of the prevalence of the variant in a relevant
population by means of database searches [e.g. dbSNP (http://
www.ncbi.nlm.nih.gov/SNP), 1000 Genomes (http://browser.
1000genomes.org), and exome variant server (http://evs.gs.
washington.edu/EVS/)]. It is anticipated that pathogenic
variants will have a minor allele frequency <1%. The
estimate of minor allele frequency should be based on a
sample size of >150 subjects.
2. Functional characterization. The effect of each variant on
RYR1 function should be assayed by one ormore of the follow-
ing test systems.
• Recombinant in vitro expression on a deﬁned genetic
background. The standard system, introduced by
D. H. MacLennan’s group, uses the expression of a rabbit
RYR1 cDNA construct (with appropriate mutations) in HEK
293 cells. Calcium release is measured ﬂuorimetrically
in response to trigger agents.46–50 Although this is a non-
muscle cell type, the advantage of the system is the deﬁned
cDNA and the standardized genetic background of the recipi-
ent cell line. This allows for direct comparison between
mutations and eliminates the potential inﬂuence of muta-
tions in other genes, which could modify RYR1 function in
cells taken frompatients. Alternatively,myotubes of the dys-
pedic mouse (RYR1 knock out) have been used as recipients
for the expression of cDNA constructs.51 Again, cDNA con-
struct and genetic background are well deﬁned and standar-
dized. The genetic expression proﬁle of myotubes may be
closer to mature muscle. For this reason, results may not
be directly comparable to the HEK 293 system.
• Assays of RYR1 function in ex vivo tissues. Calciummeasure-
ments and ligand-binding studies have been performed on
tissues fromMHS patients with characterized RYR1 variants,
inmyotubes,52 53 inmicrosomal sarcoplasmic reticulumpre-
parations from muscle biopsies,54 and in lymphoblasts.55 56
Interpretation of altered RYR1 function was based on Ca2+
ﬂux and resting [Ca2+] or ryanodine binding to sarcoplasmic
reticulum RYR1 preparations. Myotubes and lymphoblasts
were derived from individual patients and, therefore, the po-
tential inﬂuence of other individual genetic factors cannot
be excluded. For the sarcoplasmic reticulum preparations,
muscle biopsies of several patientswere pooled, thus elimin-
ating individual variation. In order to avoid the interference
of genetic factors other than RYR1, it is recommended that all
assays which are based on cells obtained from patients
should be performed on samples fromat least two independ-
ent patients with the same mutation.
3. Criteria for inclusion on EMHG list of diagnostic variants.Gen-
etic and functional characterization both must be consistent
with a pathological role in MH. For variants that have been
functionally characterized using any of the previously de-
scribed methods (section 2 above), data can be submitted
directly to the EMHG through its website. Functional data
acquired using novel methods will require validation through
publication in a peer-reviewed journal.
Disclaimer
These guidelines represent the views of the European Malignant
Hyperthermia Group. They are based on careful consideration
and interpretation of the available evidence at the time that
theywere agreed. They are intended principally for clinical scien-
tists and clinicians involved in the laboratory diagnosis of malig-
nant hyperthermia, who are encouraged to take them fully into
account when exercising their diagnostic judgement. The guide-
lines do not override the individual responsibility for laboratory
directors and diagnostic clinicians tomake appropriate decisions
and give the best advice according to the circumstances of
individual patients. Where appropriate, decisions should be
made in consultation with the patient and, where relevant,
their guardian.
Permissions
These guidelines have been developed and published by the
European Malignant Hyperthermia Group for personal and edu-
cational use only. Use for commercial purposes is not authorized.
Before any part of these guidelines are reproduced in any form,
including translations, written permission must be obtained
from the Secretary of the European Malignant Hyperthermia
Group.
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